Adaptimmune Therapeutics plc American (ADAP) Net Income by Year
Adaptimmune Therapeutics plc American reported a net loss of $70.8M in fiscal year 2024. This represents an increase of 37.8% from the prior fiscal year. Over the trailing 12 months, Q3 FY2024 through Q2 FY2025, the same line adds up to a $169.8M net loss. The table below carries 12 fiscal years, from 2013 to 2024, and the quarters Adaptimmune Therapeutics plc American has filed alongside them.
Annual figures, oldest first. Point at a bar to read its period.
ADAP Net Income by Fiscal Year
Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.
| Metric | TTM | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -$169.8M | -$70.8M+37.8% | -$113.9M+31.2% | -$165.5M-4.7% | -$158.1M-21.5% | -$130.1M+5.2% | -$137.2M-43.6% | -$95.5M-36.2% | -$70.1M+2.0% | -$71.6M-224.5% | -$22.1M-90.1% | -$11.6M-32.7% | -$8.7M |
TTM is the trailing twelve months, Q3 FY2024 through Q2 FY2025, summed from the four most recent quarterly filings.
ADAP Net Income by Quarter
Figures are as reported in USD. Each change compares the quarter with the same quarter a year earlier.
What net income means
Net income is what is left of revenue once every cost is counted, interest and tax included, so a company can grow its sales and still report a loss on this line.
More Adaptimmune Therapeutics plc American financials
Frequently Asked Questions
What was Adaptimmune Therapeutics plc American's net income in fiscal year 2024?
Adaptimmune Therapeutics plc American reported a net loss of $70.8M in fiscal year 2024.
How fast is Adaptimmune Therapeutics plc American's net income growing?
Adaptimmune Therapeutics plc American (ADAP) net income rose by 37.8% year over year, from -$113.9M to -$70.8M in fiscal year 2024.
What is Adaptimmune Therapeutics plc American's net income over the last twelve months?
Adaptimmune Therapeutics plc American (ADAP) reported a $169.8M net loss over the trailing 12 months, Q3 FY2024 through Q2 FY2025, summed from the four most recent quarterly filings.
How has Adaptimmune Therapeutics plc American's net income changed over the years?
Across the 12 fiscal years this page covers, Adaptimmune Therapeutics plc American (ADAP) net income went from -$8.7M in fiscal year 2013 to -$70.8M in fiscal year 2024.
What was Adaptimmune Therapeutics plc American's net income in the most recent quarter?
Adaptimmune Therapeutics plc American (ADAP) reported -$30.3M in net income in Q2 2025. This represents a decrease of 143.6% from the same quarter a year earlier.
What does net income mean on a financial statement?
Net income is what is left of revenue once every cost is counted, interest and tax included, so a company can grow its sales and still report a loss on this line. This page lists what Adaptimmune Therapeutics plc American (ADAP) reported on that line in every period on record.